Skip to main content
OpenTrials

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

2,679 public trials 155 recruiting studies
Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

NCT01326026

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Birmingham, Alabama, United States
  • Novo Nordisk Investigational Site Huntsville, Alabama, United States
  • Novo Nordisk Investigational Site Anaheim, California, United States
  • Novo Nordisk Investigational Site La Jolla, California, United States
View all 45 locations
View Trial Details
Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

NCT01068665

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Huntsville, Alabama, United States
  • Novo Nordisk Investigational Site Gilbert, Arizona, United States
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Tucson, Arizona, United States
View all 116 locations
View Trial Details
Completed

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

NCT01388361

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Concord, California, United States
  • Novo Nordisk Investigational Site La Jolla, California, United States
  • Novo Nordisk Investigational Site Lancaster, California, United States
  • Novo Nordisk Investigational Site Los Angeles, California, United States
View all 124 locations
View Trial Details
Completed

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

NCT01046110

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Huntsville, Alabama, United States
  • Novo Nordisk Investigational Site Concord, California, United States
  • Novo Nordisk Investigational Site Fresno, California, United States
  • Novo Nordisk Investigational Site Greenbrae, California, United States
View all 93 locations
View Trial Details
Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

NCT02000700

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • Little Rock, Arkansas, United States
  • Los Angeles, California, United States
  • Aurora, Colorado, United States
  • New Haven, Connecticut, United States
View all 17 locations
View Trial Details
Completed

A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)

NCT01868542

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Daejeon, South Korea
  • Novo Nordisk Investigational Site Daejeon, South Korea
  • Novo Nordisk Investigational Site Daejeon, South Korea
  • Novo Nordisk Investigational Site Daejeon, South Korea
View Trial Details
Completed

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496

Conditions
Cardiovascular Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 2, +6 more
Locations
  • Birmingham, Alabama, United States
  • Gulf Shores, Alabama, United States
  • Avondale, Arizona, United States
  • Phoenix, Arizona, United States
View all 57 locations
View Trial Details
Completed

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00611884

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Inglewood, California, United States
  • Novo Nordisk Investigational Site Los Angeles, California, United States
  • Novo Nordisk Investigational Site Redlands, California, United States
  • Novo Nordisk Investigational Site Spring Valley, California, United States
View all 29 locations
View Trial Details

Related conditions